Page 1

ARIX Arix Bioscience plc Interim Results for the Six Months Ended 30 June 2021 LONDON , 12 August 2021 : Arix Bioscience plc ( " Arix " , LSE : ARIX ) a global venture capital company focused on investing in and building breakthrough biotech companies , today announces its interim results for the period ended 30 June 2021 . Financial highlights Net Asset Value of £ 281.2 million ( December 2020 : £ 328.2 million ) ; 214p per share ( December 2020 : 242p ) ; a 12 % decrease in NAV per share for the first six months of 2021 Net downward portfolio revaluation of £ 32.5 million¹ in the period , predominantly due to volatility in the public portfolio Gross Portfolio Value of £ 115.2 million ( December 2020 : £ 152.1 million ) , following significant realisations Cash of £ 163.8 million ( December 2020 : £ 174.4 million ) ; £ 27.6 million of capital deployed and £ 32.0 million of capital realised during the period 24 % IRR generated by the Gross Portfolio since inception in 2016 ■ ■ Operational and strategic progress ● Launched buyback programme of up to £ 25 million ; £ 8 million of shares purchased during the period One new company added to the portfolio ; Arix led the $ 152 million Series B financing for Pyxis Oncology , taking a 5.6 % ownership stake Closed down Quench Bio after reviewing initial pre - clinical work , demonstrating disciplined approach to capital deployment and risk management Focus on improving corporate governance ; CEO and Chairman roles split , with Peregrine Moncreiffe appointed as Chairman and Robert Lyne appointed as interim CEO and board director Mark Chin , appointed as Managing Director , adding significant expertise in early to late - stage venture investing Continued focus on building the investment team , adding new talent to deploy investment capital and manage the Company's existing portfolio Portfolio highlights Despite the challenges faced as a result of COVID - 19 , Arix portfolio companies continued to make strong clinical and operational progress during the period . Notably : ● Amplyx Pharmaceuticals was acquired by Pfizer , following strong Phase 2 clinical data from its lead product candidate , Fosmanogepix in invasive fungal infections Continued clinical progress in the portfolio with data readouts from Harpoon , Imara and Autolus and new trial initiations from LogicBio , Harpoon , Artios and Autolus Artios entered into a strategic collaboration with Novartis ( $ 20 million upfront payment ) and LogicBio entered into a strategic collaboration with CANbridge Pharmaceuticals ( $ 10 million upfront payment ) Arix portfolio companies have collectively raised over $ 690 million in 2021 putting them in a strong position to execute on their important clinical development programmes . Autolus and Harpoon completed public offerings on Nasdaq during the period , raising approximately $ 130² million collectively New portfolio company , Pyxis raised $ 152 million in a Series B financing during the period ; Arix invested £ 10.8 million Aura raised $ 80 million in a Series E financing during the period ; Arix invested £ 1.3million Artios raised $ 153m in a Series C financing post period end ; Arix invested £ 6.3 million and continues to be the largest shareholder Imara completed a $ 50 million public offering on Nasdaq post period end ; Arix invested £ 5.8 million 1 Including FX 2 Additionally , Autolus raised approximately $ 29.6m of net proceeds under its Open Market Sales Agreement with Jefferies LLC in the first half of 2021 1